SARTAN VE TÜREVLERİNİ İÇEREN İLAÇLARDA N-NİTROSODİMETİL AMİN (NDMA) VE N-NİTROSODİETİL AMİN (NDEA) TAYİNİ

Öz

Amaç: Bu çalışmada, sartan ve türevlerini içeren ilaçların N-nitrosodimetil amin (NDMA) ve N-nitroso dietil amin (NDEA) miktarlarının belirlenmesi amaçlanmıştır. Gereç ve Yöntem: Etken madde olarak valsartan, losartan, telmisartan, olmesartan, kandesartan, irbesartan gibi sartan ve türevlerini içeren ilaçlar eczanelerden satın alınmıştır. İlaçların NDMA ve NDEA miktarları headspace GC-MS ile belirlenmiştir. Sonuç ve Tartışma: En yüksek NDMA konsantrasyonu losartan etken maddeli ilaçlarda (67.05 ± 0.15 mg kg-1), en yüksek NDEA konsantrasyonu ise kandesartan (22.48±0.06 mg kg-1) ve olmesartan (20.13 ± 0.06 mg kg-1) etken maddeli ilaçlarda bulunmuştur. Her tabletteki NDMA içerikleri 3.6x10-4-1.7x10-2 mg arasında, NDEA içerikleri ise 3.3x10-4- 8.8x10-3 mg arasında saptanmıştır. Avrupa İlaç Ajansı ve Gıda ve İlaç İdaresi tarafından belirlenen kabul edilebilir. Günlük alım limitleri NDMA için 96 ng/gün ve NDEA için 26.5 ng/gündür. Elde edilen değerlerin günde bir tablet alınsa bile kabul edilebilir alım limitlerinin üzerinde olduğu görülmüştür.

Anahtar Kelimeler

• Headspace GC-MS
• ilaç
• N-nitrosodietil amin (NDEA)
• N-nitrosodimetil amin (NDMA)
• sartan

Proje Numarası

22.YL.014

DETERMINATION OF N-NITROSODIMETHYL AMINE (NDMA) AND N-NITROSODIETHYL AMINE (NDEA) IN MEDICINES CONTAINING SARTAN AND ITS DERIVATIVES

Öz

Objective: In this study, it was aimed to determine the amounts of N-nitrosodimethyl amine (NDMA) and N-nitrosodiethyl amine (NDEA) in drugs containing sartan and its derivatives. Material and Method: Medicines containing sartan and its derivatives as active ingredients such as valsartan, losartan, telmisartan, olmesartan, candesartan, irbesartan were purchased from pharmacies. NDMA and NDEA amounts of drugs were determined by headspace GC-MS. Result and Discussion: The highest NDMA concentrations were found in drugs with losartan active ingredient (67.05±0.15mg kg-1), and the highest NDEA concentrations were found in drugs with candesartan (22.48±0.06 mg kg-1) and olmesartan (20.13 ± 0.06 mg kg-1) active ingredient. The NDMA contents in each tablet were between 3.6x10-4- 1.7x10-2 mg and the NDEA contents were between 3.3x10-4 – 8.8x10-3 mg. The acceptable daily intake limits specified by the European Medicines Agency and the Food and Drug Administration are 96 ng/day for NDMA and 26.5 ng/day for NDEA. It was observed that the values obtained were above the acceptable intake limits even if one tablet was taken per day.

Anahtar Kelimeler

• Drug
• headspace GC-MS
• N-nitrosodiethyl amine (NDEA)
• N-nitrosodimethyl amine (NDMA)
• sartan

Destekleyen Kurum

Hatay Mustafa Kemal University

Proje Numarası

22.YL.014

Etik Beyan

Etik belgesi gerekmemektedir.

Teşekkür

This research (22.YL.014) was supported by the Scientific Research Projects Coordination Unit of Hatay Mustafa Kemal University. The authors would like to thank the Scientific Research Projects Coordination Unit of Hatay Mustafa Kemal University for financial support.

Kaynakça

1. 1. Yuan, Y., Meng, W., Yutian, M., Fang, C., Xiaosong, H. (2015). Determination of eight volatile nitrosamines in meat products by ultrasonic solvent extraction and gas chromatography-mass spectrometry method. International Journal of Food Properties, 18(6), 1181-1190. [CrossRef]
2. 2. Honikel, K.O. (2008). The use and control of nitrate and nitrite for the processing of meat products. Meat Science, 78(1-2), 68-76.‏ [CrossRef]
3. 3. Sedlo, I., Kolonic, T., Tomic, S. (2021). Presence of nitrosamine impurities in medicinal products. Archives of Industrial Hygiene and Toxicology, 72, 1-5. [CrossRef]
4. 4. Shaikh, T., Gosar, A., Sayyed, H. (2020). Nitrosamine impurities in drug substances and drug products. Journal of Advances in Pharmacy Practices, 2(1), 48-57.
5. 5. Food and Drug Administration (September, 2020). Control of Nitrosamine Impurities in Human Drugs. From https://www.fda.gov.
6. 6. Doshi, C., Malayandi, R., Namjoshi, G., Kadam, P., Mule, D. (2021). Nitrosodimethyl amine impurities in metformin drug products physician insight. Journal of Diabetology, 12(2), 120-127. [CrossRef]
7. 7. Food and Drug Administration (September, 2022). FDA works to avoid shortage of sitagliptin following detection of nitrosamine impurity. From https://www.fda.gov.
8. 8. Tsutsumi, T., Akiyama, H., Demizu, Y., Uchiyama, N., Masada, S., Tsuji, G., Arai, R., Abe, Y., Hakamatsuka, T., Izutsu, K., Goda, Y., Okuda, H. (2019). Analysis of an impurity, N-nitrosodimethylamine, in valsartan drug substances and associated products using GC-MS. Biological and Pharmaceutical Bulletin, 42, 547-551. [CrossRef]

9. 9. Abe, Y., Yamamoto, E., Yoshida, H., Usui, A., Tomita, N., Kanno, H., Masada, S., Yokoo, H., Tsuji, G., Uchiyama, N., Hakamatsuka, T., Demizu, Y., Izutsu, K., Goda, Y., Okuda, H. (2020). Temperature-dependent formation of N-nitrosodimethyl amine during the storage of ranitidine reagent powders and tablets. Chemical and Pharmaceutical Bulletin, 68, 1008-1012. [CrossRef]
10. 10. Zmysłowski, A., Książek, I., Szterk, A. (2020). N-nitrosodimethylamine contamination in the metformin finished products. Molecules, 25(22), 5304. [CrossRef]
11. 11. Lim, H.H., Oh, Y.S., Shin, H.S. (2020). Determination of N-nitrosodimethylamine in drug substances and products of sartans, metformin and ranitidine by precipitation and solid phase extraction and gas chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 189, 113460. [CrossRef]
12. 12. Chang, S.H., Chang, C.C., Wang, L.J., Chen, W.C., Fan, S.Y., Zang, C.Z., Hsu, Y.H., Lin, M.C., Tseng, S.H., Wang, D.Y. (2020). A multi-analyte LC-MS/MS method for screening and quantification of nitrosamines in sartans. Journal of Food and Drug Analysis, 28(2), 292-301. [CrossRef]
13. 13. Liu, J., Zhao, Z., Yang, X., Jin, Y., Liu, X., Wang, C., Zhang, Z. (2021). Determination of N-nitroso dimethylamine in ranitidine dosage forms by ESI-LC-MS/MS; applications for routine laboratory testing. Iranian Journal of Pharmaceutical Research, 20(4), 255-264.
14. 14. Campillo, N., Vinas, P., Martínez-Castillo, N., Hernández-Córdoba, M. (2021). Determination of volatile nitrosamines in meat products by microwave-assisted extraction and dispersive liquid-liquid microextraction coupled to gas chromatography mass spectrometry. Journal of Chromatography A, 1218(14), 1815-1821. [CrossRef]
15. 15. Keire, D. A., Bream, R., Wollein, U., Schmaler-Ripcke, J., Burchardt, A., Conti, M., Zmysłowski, A., Keizers, P., Morin, J., Poh, J., George, M., Wierer, M. (2022). International regulatory collaboration on the analysis of nitrosamines in metformin-containing medicines. The AAPS Journal, 24(3), 56. [CrossRef]
16. 16. Vogel, M., Norwig, J. (2022). Analysis of genotoxic N-nitrosamines in active pharmaceutical ingredients and market authorized products in low abundance by means of liquid chromatography–tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 219, 114910. [CrossRef]
17. 17. Tay, K.S.J., Breadmore, M.C., Soh, E.S., See, H.H. (2022). Development of dispersive inclusion complex microextraction for the analysis of nitrosamines in medicinal products. Journal of Chromatography A, 1685, 463605. [CrossRef]
18. 18. Tarawneh, I.N., Shmeis, R.A., Alfuqaha, S.M., Al Omari, M.M. (2022). Determination of N-nitroso dimethylamine impurity in valsartan by HPLC and LC-MS/MS methods. Chinese Journal of Analytical Chemistry, 50(11), 100150. [CrossRef]
19. 19. Zhang, J., Selaya, S.D., Shakleya, D., Mohammad, A., Faustino, P.J. (2023). Rapid quantitation of four nitrosamine impurities in angiotensin receptor blocker drug substances. Journal of Pharmaceutical Sciences, 112(5), 1246-1254. [CrossRef]
20. 20. U.S. Food & Drug Administration (2019). Combined N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) impurity assay by GC/MS-Headspace. From www.fda.gov/media/117843/download.
21. 21. Luo, F., Liu, Y., Xie, Y., Hou, W., Zhang, L., Zhang, Z. (2022). Simultaneous determination of 13 nitrosamine impurities in biological medicines using salting-out liquid-liquid extraction coupled with liquid chromatography tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 218, 114867. [CrossRef]
22. 22. Chang, S.H., Ho, H.Y., Zang, C.Z., Hsu, Y.H., Lin, M.C., Tseng, S.H., Wang, D.Y. (2021). Screening of nitrosamine impurities in sartan pharmaceuticals by GC-MS/MS. Mass Spectrometry Letters, 12(2), 31-40.